Table: Santen Pharm -9-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

07/02/2023 06:00

Feb 7 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended        Year to  
                  Dec 31, 2022        Dec 31, 2021      Mar 31, 2023  
                     LATEST             YEAR-AGO           COMPANY    
                     RESULTS             RESULT           FORECAST    
  Sales              199.79              195.80            272.00     
                   (+2.0 pct)          (+7.7 pct)        (+2.2 pct)   
  Operating        loss 10.15             26.38           loss 6.50   
                                       (-2.0 pct)                     
  Pretax           loss 11.59             25.67           loss 8.50   
                                       (-3.5 pct)                     
  Net              loss 16.06             19.35                       
                                       (-7.9 pct)                     
  EPS Basic      loss 41.13 yen         48.39 yen      loss 40.01 yen 
  EPS Diluted    loss 41.13 yen         48.32 yen                     
  Ann Div                               32.00 yen         32.00 yen   
  -Q2 Div           16.00 yen           16.00 yen                     
  -Q4 Div                               16.00 yen         16.00 yen   
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T